arrow
B

Bruce Montgomery

Fred Hutchinson Cancer Center
H指数:62
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating Tumor Cell Synaptophysin and Androgen Receptor Expression Reflect Prostate Cancer Phenotypes in Metastatic Disease

循环肿瘤细胞突触素和雄激素受体表达反映转移性前列腺癌的表型

2026-10-120
OAAI
Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans

克隆性造血对cfDNA液体活检检测的干扰及在美国退伍军人大型多样化队列中可操作变异的识别

2026-07-210
OAAI
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study
Cancer
IF5.1
2026-01-300
OAAI
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study

膀胱癌亚型组织学患者中经尿道膀胱肿瘤切除术与根治性膀胱切除术病理结果的一致性:一项回顾性队列研究

2025-11-010
PRE
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial

新辅助帕博利珠单抗联合加速甲氨蝶呤、长春碱、多柔比星和顺铂在非尿路上皮性肌层浸润性膀胱癌不同组织学亚型中的应用:一项II期临床试验

2025-08-050
PRE
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency

多西他赛和卡铂诱导治疗伴DNA同源重组修复缺陷的转移性去势抵抗性前列腺癌患者的2期研究结果

2025-05-230
PRE
Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

德诺veau转移性激素敏感性前列腺癌患者的治疗模式与生存情况

2025-05-080
OA
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2025-02-070
PRE
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings

基于PET的TheraP资格及VISION试验合格患者中接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者的结局:18F-FDG显像不一致结果的重要性

2024-11-141
PRE
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
2024-05-173
OAAI
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
2022-12-239
OA